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Abstract
Background: Vancomycin has been used in clinical practice for over 50 years; however, validated, pharmacokinetic (PK)
data relating clinical outcomes to different dosing regimens in neonates are lacking. Coagulase negative staphylococci
(CoNS) are the most commonly isolated organisms in neonatal, late-onset sepsis (LOS). Optimised use to maximise
efficacy while minimising toxicity and resistance selection is imperative to ensure vancomycin’s continued efficacy.
Methods: NeoVanc is a European, open-label, Phase IIb, randomised, controlled, non-inferiority trial comparing an
optimised vancomycin regimen to a standard vancomycin regimen when treating LOS known/suspected to be caused
by Gram-positive organisms (excluding Staphylococcus aureus) in infants aged ≤ 90 days. Three hundred infants will be
recruited and randomised in a 1:1 ratio. Infants can be recruited if they have culture confirmed (a positive culture from a
normally sterile site and at least one clinical/laboratory criterion) or clinical sepsis (presence of any ≥ 3 clinical/laboratory
criteria) in the 24 h before randomisation.
The optimised regimen consists of a vancomycin loading dose (25 mg/kg) followed by 5 ± 1 days of 15 mg/kg q12h or
q8h, dependent on postmenstrual age (PMA). The standard regimen is a 10 ± 2 day vancomycin course at 15mg/kg
q24h, q12h or q8h, dependent on PMA.
The primary endpoint is a successful outcome at the test of cure visit (10 ± 1 days after the end of vancomycin therapy).
A successful outcome consists of the patient being alive, having successfully completed study vancomycin therapy and
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having not had a clinical/microbiological relapse/new infection requiring treatment with vancomycin or other anti-
staphylococcal antibiotic for > 24 h.
Secondary endpoints include clinical/microbiological relapse/new infection at the short-term follow-up visit (30 ± 5 days
after the initiation of vancomycin), evaluation of safety (renal/hearing), vancomycin PK and assessment of a host
biomarker panel over the course of vancomycin therapy.
Discussion: Based on previous pre-clinical data and a large meta-analysis of neonatal, PK/pharmacodynamic data, NeoVanc
was set up to provide evidence on whether a loading dose followed by a short vancomycin course is non-inferior, regarding
efficacy, when compared to a standard, longer course. If non-inferiority is demonstrated, this would support adoption of the
optimised regimen as a way of safely reducing vancomycin exposure when treating neonatal, Gram-positive LOS.
Trial registration: ClinicalTrials.gov, NCT02790996. Registered on 7 April 2016.
EudraCT, 2015–000203-89. Entered on 18 July 2016.
Keywords: Neonate, Late-onset sepsis, Vancomycin, coagulase negative staphylococci, Randomised controlled trial, Non-
inferiority, Loading dose
Background
Neonatal late-onset sepsis
Neonatal late-onset sepsis (LOS) is defined as sepsis occur-
ring 48–72 h after birth. The causative organisms associ-
ated with neonatal LOS tend to be those found in the
neonatal intensive care unit (NICU) or are normal skin or
gut commensals. Coagulase negative staphylococci (CoNS)
are the most commonly recovered organisms from the
blood cultures of neonates with LOS. Overall mortality
rates secondary to CoNS are reported as < 2% in resource-
rich settings; however, this increases to ~ 9% in very low
birth weight (VLBW) and preterm infants [1–4]. CoNS-
associated LOS has a significant morbidity with episodes of
LOS having an adverse effect on neurodevelopmental out-
comes as well as increasing the cost of hospitalisation, pri-
marily due to prolonged length of stay [1, 5–8].
Interventions on the NICU are often invasive, e.g. central
venous catheters, and these can increase a neonate’s expos-
ure to hospital-acquired pathogens such as CoNS [1].
Diagnosis of neonatal sepsis
Diagnosing neonatal sepsis can be difficult, particularly
as clinical signs of sepsis can frequently overlap with dis-
orders unrelated to sepsis [9]. Blood culture positivity
rates in neonates are low [10] and pharmacodynamic
(PD) markers, such as C-reactive protein (CRP) can
demonstrate variable results in neonates, particularly
preterm and VLBW babies [11, 12]. Novel methods for
diagnosing neonatal sepsis such as biomarkers based on
host RNA are under development. A prospective, case-
control study provided clinically validated evidence that
host RNA from whole blood can serve as a causally rele-
vant biomarker for detecting neonatal infection [13, 14].
Vancomycin use and emerging antimicrobial resistance
Glycopeptides are the most commonly prescribed antibi-
otics in children for hospital-acquired infections in Latin
America, North America, Australia and Europe, with
vancomycin being one of the most widely utilised antibi-
otics in the treatment of Gram-positive sepsis. Methicil-
lin and gentamicin resistances in CoNS are reported as
85% and in the range of 32%-94%, respectively [15–18];
vancomycin is, therefore, a first-line therapy in sepsis
due to CoNS [19].
It is well-known that high rates of antibiotic use are
associated with antimicrobial resistance [20–22]. The
wide variation in vancomycin dosing and monitoring
practices seen across NICUs demonstrates that optimal
dosing and monitoring regimens are not well standar-
dised in this population [23] and highly variable between
countries and centres [24]. One UK study revealed 17
different combinations of dose, timing of dose and tim-
ing of monitoring [25]. Current vancomycin-dosing regi-
mens recommended for preterm neonates, such as those
in the European Society for Paediatric Infectious Dis-
eases Manual of Childhood Infection – The Blue Book
and the British National Formulary for Children, are
based on expert opinion or on studies including only a
small number of babies rather than on data generated
from clinical trials [26–28].
The wider impact of different vancomycin-dosing regi-
mens and course durations on normal, neonatal, gut and
skin flora are not known. However, antibiotic use can
lead to the disruption of the microbiome leading to col-
onisation with resistant bacteria and candida [5, 29, 30].
Colonisation with vancomycin-resistant enterococci and
candida are known risk factors for invasive infection
with associated morbidity and mortality [31, 32].
Trial concept
In view of the lack of validated, neonatal, vancomycin
pharmacokinetic (PK), safety and efficacy data to support
optimal use, the European Medicines Agency (EMA) in-
cluded vancomycin on its ‘Revised priority list for studies
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into off-patent paediatric medicinal products’. The EMA
called for more data on the optimal dosing and monitor-
ing regimens for preterm and term neonates with sepsis
caused by staphylococci and non-pyogenic streptococci
[33]. It was advised that new data should be generated
from PK/PD and safety-based efficacy studies. The Neo-
Vanc project has been developed in direct response as a
planned drug discovery programme. The discovery and
licencing of new antibiotics is a lengthy process; there-
fore, ascertaining optimal dosing of the older, off-patent
vancomycin is essential to ensure the continued efficacy
of this important antibiotic in the treatment of neonatal
LOS [34].
Methods and trial design
Objectives
The primary objective of the NeoVanc trial is to com-
pare the efficacy of an optimised vancomycin-dosing
regimen to a standard vancomycin-dosing regimen in
patients with LOS, known or suspected to be caused by
Gram-positive microorganisms.
The Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) checklist is provided in
Additional file 1.
Study design and selection of optimised dosing regimen
The NeoVanc clinical trial (www.neovanc.org) is an
open-label, European, multi-centre, Phase IIb, rando-
mised, active control, parallel group, non-inferiority trial.
A total of 300 participants are expected to be enrolled
from approximately 20 NICUs in five European Union
countries (Estonia, Greece, Italy, Spain and the United
Kingdom).
The NeoVanc project forms part of a Paediatric Inves-
tigation Plan (PIP) which has received a favourable opin-
ion from the EMA Paediatric Committee (PDCO). The
clinical trial, as part of the PIP, aims to provide data on
dosing, efficacy and safety of vancomycin in neonates,
which will lead to a Paediatric-Use Marketing Authorisa-
tion (PUMA) application.
The pre-clinical studies—(1) a hollow-fibre infection
model, a rabbit model [35] and a staphylococcal biofilm
in vitro model [36]; and (2) a population pharmacoki-
netic meta-analysis of neonatal, vancomycin studies [37]
to define the optimal dosing regimen for the clinical
trial—are detailed in Fig. 1.
Ethical approval has been gained in all participating
European countries as well as approvals from the rele-
vant Regulatory and Ethics Authorities.
Study participants
Infants admitted to the NICU with suspected/confirmed
LOS. Participants can be recruited if they fulfil the inclu-
sion criteria and have none of the exclusion criteria.
Inclusion criteria
The inclusion criteria for the clinical trial are adapted
from the European Medicines Agency definition for
neonatal LOS [38].
 Postnatal age ≤ 90 days at randomisation
AND
 Postnatal age ≥ 72 h at onset of sepsis
AND
 Clinical sepsis as defined by presence of any three
clinical or laboratory criteria from the list below, in
the 24 h before randomisation
OR
 Confirmed, significant bacterial sepsis as defined by
positive culture with a Gram-positive bacterium
from a normally sterile site and at least one clinical
or one laboratory criterion from the list below, in
the 24 h before randomisation.
Clinical criteria
 Hyperthermia or hypothermia
 Hypotension or impaired peripheral perfusion or
mottled skin
 Apnoea or increased oxygen requirement or
increased requirement for ventilatory support
 Bradycardic episodes or tachycardia
 Worsening feeding intolerance or abdominal
distension
 Lethargy or hypotonia or irritability
Laboratory criteria
 White blood cell (WBC) count < 4 or > 20 × 109 cells/L
 Immature to total neutrophil ratio (I/T) > 0.2
 Platelet count < 100 × 109/L
 CRP > 10 mg/L
 Glucose intolerance as defined by a blood glucose
value > 180 mg/dL (> 10 mmol/L) when receiving
normal glucose amounts (8–15 g/kg/day)
 Metabolic acidosis as defined by a base excess
(BE) < − 10 mmol/L (< − 10 mEq/L) or a blood
lactate value > 2 mmol/L
Exclusion criteria
 Administration of any systemic antibiotic regimen
for > 24 h before randomisation, unless the change
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is driven by the apparent lack of efficacy of the
original regimen
 Treatment with vancomycin for ≥ 24 h at any time
within 7 days of randomisation
 Known toxicity, hypersensitivity or intolerance to vancomycin
 Known acute renal impairment as defined by urinary
output < 0.7 mL/kg/h for 24 h or a creatinine value
≥ 10 μmol/L (1.13 mg/dL)
 Patient receiving (or planned to receive)
haemofiltration, haemodialysis, peritoneal dialysis,
Fig. 1 NeoVanc flow chart demonstrating how the pre-clinical studies, NeoVanc-1 (hollow fibre infection and rabbit models) and NeoVanc-2
(population pharmacokinetics meta-analysis) advised the dosing for the optimised arm of the NeoVanc Clinical Trial (NeoVanc-3)
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extracorporeal membrane oxygenation (ECMO) or
cardiopulmonary bypass
 Severe congenital malformations where the infant is
not expected to survive for > 3 months
 Patient known to have S. aureus (MSSA or MRSA)
bacteraemia
 Patient with osteomyelitis, septic arthritis, urinary
tract infection (UTI) or meningitis
 Patient with high suspicion of/confirmed sepsis
caused by Gram-negative organisms or fungi
 Other situations where the treating physician
considers a different empiric antibiotic regimen
necessary
 Current participation in any other clinical study of
an investigational medicinal product (IMP)
Post-randomisation exclusions
 Any participant found to have Gram-negative or
fungal sepsis, osteomyelitis, septic arthritis, urinary
tract infection, meningitis or S. aureus (MSSA or
MRSA) bacteraemia after randomisation will be ex-
cluded from the efficacy analysis but followed up for
safety.
Dosing schedule by arm
Standard regimen: 15 mg/kg q24h (PMA < 29 weeks),
q12h (PMA 29–35 weeks) or q8h PMA > 35 weeks. Dur-
ation is 10 ± 2 days. Optimised regimen: all participants
receive a single loading dose of 25 mg/kg followed by a
maintenance dose of 15 mg/kg q12h (PMA ≤ 35 weeks)
or q8h (PMA > 35 weeks). Duration is 5 ± 1 days. Dose
adjustments should only occur within the context of
routine therapeutic drug monitoring. The only exception
is if renal impairment develops, when study vancomycin
dose may be adjusted dependent on vancomycin levels/
local practice.
Concomitant antibiotics
Use of concomitant antibiotics during vancomycin ther-
apy is allowed except for specific anti-staphylococcal
agents (flucloxacillin, oxacillin, linezolid, tedizolid, dap-
tomycin and teicoplanin).
Assignment of interventions
Infants will be randomised in a 1:1 ratio to either the
standard treatment regimen or the optimised treatment
regimen. Randomisation will be managed via a secure
web-based randomisation facility. The randomisation
program will use a minimisation algorithm to ensure
balance between the groups with respect to clinical
centre, PMA at randomisation, and presence or absence
of an umbilical catheter/central venous line.
Local investigators and participants’ parents/guardians
will not be blinded to regimen allocation as this is an
open label study. Investigators undertaking the bio-
marker and microbiological sub-analyses will be blinded
to arm allocation. The trial management group and trial
data analysts will be blinded to aggregate outcomes from
interim analyses; unblinding will, therefore, not occur.
Primary outcome measure
The primary outcome incorporates clinical and micro-
biological factors. Successful outcome at the Test of
Cure (TOC) visit (10 ± 1 days after the end of actual
vancomycin therapy [EVT])
 Participant is alive
and
 Successful outcome at EVT (defined as the
participant is alive, there is a significant
improvement in the participant’s overall, clinical
status, there is microbiological resolution or
presumed eradication of bacteria and no new
vancomycin-susceptible pathogens potentially asso-
ciated with sepsis have been identified)
and
 Participant has not had a clinically or
microbiologically significant relapse or new
infection, requiring treatment with vancomycin or
other specific anti-staphylococcal antibiotics (flu-
cloxacillin, oxacillin, linezolid, tedizolid, daptomycin
and teicoplanin) for > 24 h within 10 days of EVT
visit
Secondary outcome measures
 Evaluation of efficacy
– Clinically or microbiologically, significant relapse
or new infection within 10 days of EVT, requiring
treatment with any antibiotic (other than
vancomycin or specific anti-staphylococcal antibi-
otics [flucloxacillin, oxacillin, linezolid, tedizolid,
daptomycin and teicoplanin]) for > 24 h
– Clinically significant relapse or new infection at
short-term follow-up (STFU; 30 ± 5 days from
initiation of study vancomycin) visit
 Evaluation of safety by allocation group
– Abnormal renal function tests at the STFU visit
– Abnormal hearing screening test
– Comparative safety of vancomycin (related to all
other parameters other than renal and hearing
safety) at STFU visit
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 PK/PD evaluation
– PK parameters of vancomycin using population
PK modelling by allocation group
– Probability of target attainment with different
study regimens
 Microbiological evaluation
– Relationship between CoNS species and duration
of treatment and CRP response
– Gut, skin and mucosal colonisation by
vancomycin resistant organisms at baseline, EVT
and STFU visit
– Bacterial DNA polymerase chain reaction (PCR)
analysis in babies ≥ 29 weeks PMA
 Biomarker evaluation
– Assessment of changes in host biomarker panel
profiles [13, 14] from baseline to EVT and the
relationship between host biomarker and
duration of treatment
Study procedures
Recruitment and consent
The parent(s)/guardian(s) of potential participants are
approached by research staff to assess eligibility, provide
information and obtain informed consent. Informed
consent is only gained after information has been pro-
vided, questions have been answered and time has been
given for consideration. If consent is gained, the in-
formed consent form is signed by the parents/guardians
before study recruitment according to the national eth-
ical regulations of the participating countries. Parents/
guardians can also pre-consent to the trial. In this case,
the same procedure applies; however, parents/guardians
are approached before their baby becomes unwell. If
pre-consent is in place and a baby develops signs of sep-
sis and meets the eligibility criteria, the parents/guard-
ians can be contacted via telephone or in person to
confirm continued consent.
Consent for the trial as well as the PK and microbio-
logical sub-analyses are gained together; information is
provided in relation to all sub-analyses in the participant
information sheet and informed consent form. Partici-
pants’ parents/guardians will also be asked for permis-
sion for the research team to share relevant data with
people from the organisations taking part in the research
or from regulatory authorities, where relevant. A copy of
the informed consent form can be provided by the cor-
responding author on request.
Visits
Eight visits are planned, from the neonate’s screening
and randomisation to the audiology follow-up visit and
will be performed as outlined in Table 1 – Schedule of
Study Assessments for the NeoVanc Clinical Trial.
Monitoring of clinical and laboratory parameters
Participants will be monitored for specific clinical signs
and laboratory parameters in line with the EMA’s cri-
teria for the diagnosis of neonatal sepsis, at day 3, day 5
± 1 and day 10 ± 2 (standard arm only) [38], so as to de-
termine the rate of recovery. At EVT, an assessment will
be made according to specified criteria as to whether the
baby has had a significant improvement in their overall,
clinical status. Participants who have met this criteria
will proceed to the TOC visit where an assessment to
determine whether the baby has had a clinically signifi-
cant new infection (three clinical or laboratory signs),
microbiological relapse (positive blood culture with
phenotypically similar organism + one clinical/laboratory
sign) or microbiological new infection (positive blood
culture with an organism of interest + one clinical/la-
boratory sign) which has required > 24 h of anti-
staphylococcal antibiotics since the EVT visit. All partic-
ipants will undergo hearing screening.
Study-specific assessments
Blood isolates
Blood culture will be collected at baseline and subse-
quently if positive. Isolates will be stored and sent to the
central microbiology laboratory for identification and anti-
microbial susceptibility testing. Relevant isolates will be
tested for biofilm production and biofilm susceptibility.
Bacterial DNA PCR
Bacterial DNA PCR will be utilised in the identification
of causative organisms where the blood culture is nega-
tive, as well as quantitative analysis as a PD marker. Bac-
terial DNA analysis will only take place in those infants
who are ≥ 29 weeks PMA in view of the restrictions on
the blood volumes allowed in clinical trials. Samples are
taken at baseline, Visit 3 and the STFU visit.
Disruption of normal colonising flora
Stool (or rectal swab if stool unavailable) as well as axilla
and nasal swabs will be collected at baseline, EVT and at
the STFU visit to assess the impact of vancomycin on gut,
skin and mucosal flora. Babies will be screened for
vancomycin-resistant enterococci, candida and a subset
for CoNS with reduced susceptibility to vancomycin, which
will all be used as surrogate markers of disruption to nor-
mal flora. It will be determined whether colonisation with
these organisms changes over the treatment course, as well
as between specific groups, e.g. preterm versus term babies.
Biomarkers
A set of biomarkers will be performed as a classifier with
high accuracy in predicting specifically bacterial infec-
tion. Biomarkers samples are taken at baseline, visits 3,
4, 5 (standard arm only) and the STFU visit.
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Sample size
This is a non-inferiority study comparing a standard
regimen and an optimised regimen. It is hypothesised
that 95% of the participants in the standard treatment
arm will not require a second course of treatment
with anti-staphylococcal antibiotics and that the pro-
portion will be the same in the optimised treatment
group. Using the Wilson-score method, a sample size
of 150 babies per arm will give at least 90% of power
to demonstrate a non-inferiority margin of 10% (nQu-
ery Software, ‘Statsols’; Statistical Solutions Ltd., Cork,
Ireland).
Statistical analysis
Analysis of the primary outcome will be performed using
binomial regression with an identity link to report the
risk difference and its 95% confidence interval (CI) (risk
of a successful outcome at TOC visit in the optimised
regimen – risk in the standard regimen). The optimised
regimen will be considered non-inferior if the lower
limit of the 95% CI is ≥ − 10%. Non-inferiority of the
optimised regimen will be tested using a one-sided test
at the 2.5% level of significance.
An unadjusted analysis will be carried out as well
as an adjusted analysis, adjusting for the minimisation
factors used during randomisation by including them
as covariates – centre, PMA at randomisation (< 29
weeks/29–35 weeks/> 35 weeks), and presence or ab-
sence of an umbilical catheter/central venous line. If
there are insufficient participants in some centres to
use this as a covariate factor, the centre will be used
to adjust the variance estimator by including it as a
clustering factor. This analysis will be carried out
using both per-protocol (PP) and intention-to-treat
(ITT) populations for comparison but the primary in-
ference will be based on the adjusted analysis of the
PP population.
For the secondary outcomes, risk ratios and their 95%
CIs will be estimated using a log binomial regression
model or using a log Poisson regression model with a
robust variance estimator if the binomial model fails to
converge. The analyses will be carried out for both the
PP and ITT populations and, in each case, an unadjusted
and adjusted analysis will be carried out as described for
the primary outcome.
Pre-specified subgroup analysis will be performed for
the primary outcome using the statistical test of inter-
action, based on PMA at randomisation, birth weight
category, and presence or absence of an umbilical cath-
eter/central venous line at the onset of sepsis.
Pharmacokinetics analysis
Pharmacokinetic data will be analysed by nonlinear
mixed-effect modelling method (NONMEM). The
vancomycin plasma concentration data will be imported
into R for exploratory analysis and formatted for subse-
quent modelling using NONMEM version 6.2 (Globo-
max, USA). An interim PK analysis will be performed
when PK and scavenged samples have been obtained
from 50 participants.
Adverse event reporting
All adverse events occurring from the administration of
the first dose of study vancomycin to the final follow-up
visit will be recorded. In addition, serious adverse events,
which meet the criteria for expedited reporting, will be
reported to the Sponsor within 24 h of the awareness of
the event.
Data management
Data will be collected in an electronic case report form
which will be managed by Consorzio per Valutazioni
Biologiche e Farmacologiche. All data collected will re-
main strictly confidential and anonymous. Access to the
data is mandated by the Sponsor.
End of trial
The end of trial will be the point of database lockdown.
Committees
Network Management Group (NMG) is an executive
body comprising of NeoVanc Work Package leaders and
the Trial Statistician with decision powers over the
whole NeoVanc project, its technical development and
work plan updates. The NeoVanc Trial Management
Group is a subgroup of the NMG and comprises of the
individuals actively involved in this clinical trial. The
group is responsible for managing the operational as-
pects of the trial. The Independent Data Monitoring
Committee (IDMC) will monitor progress, safety and PK
data with the aim of protecting the safety and interests
of the trial participants and scientific integrity of the
trial. The IDMC is composed of a neonatologist, a
microbiologist and a statistician. The members of the
IDMC are independent and have no involvement with
the NeoVanc clinical trial.
Monitoring
Monitoring of the study will be performed by Therakind
Ltd. in accordance with the International Conference on
Harmonisation of Technical Requirements for Registra-
tion of Pharmaceuticals for Human Use Good Clinical
Practice guidelines, local regulations and Therakind
Standard Operating Procedures.
Audit can be performed at any time by independent,
properly authorised individuals mandated by the Spon-
sor. The audit is aimed to ensure the quality of the
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research, data accuracy, and respect of laws and
regulations.
Specific considerations
Study-specific procedures have been kept to as few as
possible and the volumes of blood to be obtained fall
well within the guidelines set out by the EMA [39].
Bacterial DNA analysis will only be undertaken in neo-
nates ≥ 29 weeks PMA. Study procedures will be carried
out at the same time as routine investigations, where
possible, to minimise discomfort.
Neonatal sepsis is serious and requires rapid treatment
initiation; therefore, it will not always be possible to gain
consent for the study within this timeframe. Up to 24 h
of antibiotic administration prior to randomisation has
been allowed within the protocol to allow for this. How-
ever, pre-consent is also allowed where consent can be
gained before a baby becoming unwell, allowing for IMP
to be initiated as soon as possible.
Trial sponsor
The trial sponsor is Fondazione PENTA Onlus (Email:
info@penta-id.org). The sponsor has not participated in
the study design and will not participate in the collec-
tion, analysis or interpretation of the data.
Discussion
Clinical trials and neonates
The NeoVanc trial opted to adapt the EMA criteria for
the diagnosis for neonatal sepsis, by allowing entry to
the trial on three clinical or laboratory signs as opposed
to requiring two clinical and two laboratory signs. The
reason for this was due to the less severe presentation
and milder sepsis course seen with CoNS [1–4].
The NeoVanc trial is an open-label study. The use of a
placebo in neonatal trials is controversial particularly if
preterm infants are included in recruitment. In studies
evaluating intravenous medication, the use of placebo
can be a challenge in view of the careful fluid balance re-
quired in this population. Blinding would be difficult in
view of the differing course lengths unless a placebo was
used for the remaining days in the short course arm. It
is recognised by the NeoVanc Consortium that this
could lead to ascertainment bias particularly in view of
the varying prescribing practices for vancomycin
throughout Europe; some clinicians may favour a short
course over a long course or vice versa [23, 25]. Investi-
gators will be strongly encouraged to adhere to the allo-
cated vancomycin duration and an assessment of the
baby’s clinical status will be undertaken on the day
vancomycin is actually stopped as well as on the day
vancomycin should have been terminated so as to ascer-
tain if the baby fulfilled the protocol’s definition of re-
covered/significantly improved.
The NeoVanc trial provides the unique opportunity to
evaluate multiple aspects of neonatal, vancomycin
pharmacokinetics within one study. Different course
lengths will be explored but also the use of a loading dose,
in the optimised arm, will help to ascertain if vancomycin
levels can be safely increased more quickly and thus allow
course duration to be reduced. More frequent dosing in
babies < 29 weeks PMA will also be assessed in the opti-
mised arm where babies receive dosing every 12 h instead
of every 24 h as in the standard arm.
Finding an acceptable balance between antibiotic re-
sistance, safety, duration and efficacy is a major chal-
lenge when treating neonatal sepsis; the NeoVanc trial
aims to focus on all four components.
Trial status
The trial opened to recruitment on 3 March 2017; the first
participant was recruited on 17 March 2017. The current
protocol version is 6.0 (dated 7 September 2016). Recruit-
ment is expected to complete by 31 December 2019.
Dissemination policy
There are no current plans for granting public access to
participant-level datasets or statistical code. Outcomes
of this trial will be published in a peer-reviewed journal.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-4184-8.
Additional file 1. SPIRIT 2013 Checklist.
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